Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study

Table 2

Treatment patterns of sintilimab.

Category or variable	No. (%) or value
No. of patients	50
Treatment line
1st line	36 (72.0)
2nd line	9 (18.0)
3rd line	5 (10.0)
Systemic treatment
Sintilimab alone	1 (2.0)
Sintilimab plus chemotherapy	44 (88.0)
Paclitaxel	2 (4.0)
Paclitaxel plus platinum	3 (6.0)
Albumin-bound paclitaxel	3 (6.0)
Albumin-bound paclitaxel plus platinum	24 (48.0)
S-1 (tegafur-gimeracil-oteracil potassium)	4 (8.0)
S-1 plus platinum	4 (8.0)
Oxaliplatin	1 (2.0)
Irinotecan	3 (6.0)
Sintilimab plus antiangiogenic therapy	5 (10.0)
Anlotinib	3 (6.0)
Apatinib	2 (4.0)
Combination of radiotherapy
Yes	24 (48.0)
No	26 (52.0)
Cycle of sintilimab (times)
Median	5
Range	2–27
Duration of sintilimab (days)
Median	119
Range	42–636